Zimmer Biomet Holdings Inc (NYSE: ZBH) has a price-to-earnings ratio that is above its average at 22.48x. The stock has a 36-month beta value of 1.03. Opinions on the stock are mixed, with 9 analysts rating it as a “buy,” 9 as “overweight,” 9 as “hold,” and 1 as “sell.”
The public float for ZBH is 203.37M, and at present, short sellers hold a 2.90% of that float. On September 25, 2024, the average trading volume of ZBH was 1.54M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ZBH) stock’s latest price update
Zimmer Biomet Holdings Inc (NYSE: ZBH) has seen a rise in its stock price by 0.22 in relation to its previous close of 107.57. However, the company has experienced a 1.48% gain in its stock price over the last five trading sessions. zacks.com reported 2024-09-06 that Zimmer (ZBH) reported earnings 30 days ago. What’s next for the stock?
ZBH’s Market Performance
Zimmer Biomet Holdings Inc (ZBH) has seen a 1.48% rise in stock performance for the week, with a -6.29% decline in the past month and a -0.38% plunge in the past quarter. The volatility ratio for the week is 1.44%, and the volatility levels for the past 30 days are at 1.73% for ZBH. The simple moving average for the past 20 days is -1.11% for ZBH’s stock, with a -8.32% simple moving average for the past 200 days.
Analysts’ Opinion of ZBH
Piper Sandler, on the other hand, stated in their research note that they expect to see ZBH reach a price target of $115, previously predicting the price at $140. The rating they have provided for ZBH stocks is “Neutral” according to the report published on July 01st, 2024.
Goldman gave a rating of “Neutral” to ZBH, setting the target price at $129 in the report published on May 30th of the current year.
ZBH Trading at -1.70% from the 50-Day Moving Average
After a stumble in the market that brought ZBH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.48% of loss for the given period.
Volatility was left at 1.73%, however, over the last 30 days, the volatility rate increased by 1.44%, as shares sank -5.95% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +1.20% upper at present.
During the last 5 trading sessions, ZBH rose by +1.48%, which changed the moving average for the period of 200-days by -7.16% in comparison to the 20-day moving average, which settled at $108.68. In addition, Zimmer Biomet Holdings Inc saw -11.41% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ZBH starting from Yi Sang, who sale 12,857 shares at the price of $114.69 back on May 31 ’24. After this action, Yi Sang now owns 5,322 shares of Zimmer Biomet Holdings Inc, valued at $1,474,582 using the latest closing price.
Yi Sang, the Group President, Asia Pacific of Zimmer Biomet Holdings Inc, sale 1,705 shares at $126.86 during a trade that took place back on Mar 07 ’24, which means that Yi Sang is holding 18,179 shares at $216,296 based on the most recent closing price.
Stock Fundamentals for ZBH
Current profitability levels for the company are sitting at:
- 0.18 for the present operating margin
- 0.66 for the gross margin
The net margin for Zimmer Biomet Holdings Inc stands at 0.13. The total capital return value is set at 0.08. Equity return is now at value 7.94, with 4.66 for asset returns.
Based on Zimmer Biomet Holdings Inc (ZBH), the company’s capital structure generated 0.31 points at debt to capital in total, while cash flow to debt ratio is standing at 0.26. The debt to equity ratio resting at 0.46. The interest coverage ratio of the stock is 6.71.
Currently, EBITDA for the company is 2.34 billion with net debt to EBITDA at 2.29. When we switch over and look at the enterprise to sales, we see a ratio of 3.64. The receivables turnover for the company is 5.31for trailing twelve months and the total asset turnover is 0.35. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.29.
Conclusion
To sum up, Zimmer Biomet Holdings Inc (ZBH) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
